scispace - formally typeset
E

Edward D. Plowey

Researcher at Stanford University

Publications -  29
Citations -  6807

Edward D. Plowey is an academic researcher from Stanford University. The author has contributed to research in topics: Autophagy & Neurodegeneration. The author has an hindex of 13, co-authored 27 publications receiving 6056 citations. Previous affiliations of Edward D. Plowey include University of Pittsburgh.

Papers
More filters
Journal ArticleDOI

Comparison of diffusion MRI and CLARITY fiber orientation estimates in both gray and white matter regions of human and primate brain.

TL;DR: In this paper, the tertiary eigenvector of structure tensors is used to estimate the three-dimensional neuronal fiber and vasculature orientations from neurofilament stained CLARITY images, and then the orientation estimates are extended to an orientation distribution function (ODF) formalism by summing multiple sub-voxel orientation estimates.
Journal ArticleDOI

Hippocampal phospho-tau/MAPT neuropathology in the fornix in Alzheimer disease: an immunohistochemical autopsy study

TL;DR: The cross-sectional autopsy findings indicate that the fornix is involved by p-MAPT neuropathology secondary to hippocampal involvement by AD neuro Pathology, and are compatible with the goal of in vivo detection of p- MAPT-related axonal pathology in theFornix in AD as a possible biomarker of p -MAPT progression from the hippocampal formation.
Journal ArticleDOI

GA binding protein augments autophagy via transcriptional activation of BECN1-PIK3C3 complex genes.

TL;DR: In this paper, GA binding protein (GABP) was identified as a transcriptional regulator of the combinatorial expression of BECN1-PIK3C3 complex genes involved in autophagosome initiation.
Journal ArticleDOI

Alzheimer disease neuropathology in a patient previously treated with aducanumab

TL;DR: In this article , an 84-year-old woman who was randomized to the placebo arm of the PRIME Phase 1b study (221AD103) showed robust Aβ plaque reduction, from a composite standard uptake value ratio (SUVR) of 1.5 at screening to < 1.1 at 56 weeks post-aducanumab dosing.